Is Cyclacel Pharmaceuticals, Inc. overvalued or undervalued?

As of 14 November 2016, Cyclacel Pharmaceuticals, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered overvalued given its financial metrics and performance. Key ratios include a price-to-book value of 2.69, an EV to EBITDA of -0.36, and a return on equity (ROE) of -272.53%, which highlight the company's struggles in generating returns and profitability.
In comparison to its peers, Cyclacel's valuation metrics are concerning. For instance, SeqLL, Inc. has a valuation grade of risky with an EV to EBITDA of -8.8835, while Hoth Therapeutics, Inc. also does not qualify with an EV to EBITDA of -0.6107. These comparisons further reinforce the notion that Cyclacel is not positioned favorably within its industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -94.56%, suggesting a lack of investor confidence and further supporting the conclusion that Cyclacel Pharmaceuticals is overvalued.